Open Payments

Ascension Seton Medical Center

Type
Teaching hospital
Where
Austin, TX
Medicare CCN
450056
Received
$1,205,705 in 328 records, 2022 ($72,079 general, $1,133,626 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment74$72,079
2022Research payment254$1,133,626

By company

CompanyRecordsAmountYears
JAZZ PHARMACEUTICALS INC.12$603,2752022
Medtronic, Inc.41$156,8772022
VERTEX PHARMACEUTICALS INCORPORATED3$85,1032022
Boston Scientific Corporation41$73,0592022
Abbott Laboratories53$67,1762022
Regeneron Pharmaceuticals, Inc.24$55,1292022
Travere Therapeutics, Inc.32$48,5722022
AngioDynamics, Inc.2$43,0002022
UCB SA1$22,7502022
Esperion Therapeutics, Inc.38$13,3162022
Merit Medical Systems Inc1$9,0252022
Terumo Medical Corporation5$6,1522022
Veryan Medical Incorporated3$3,8182022
Janssen Research & Development, LLC3$3,6502022
BTG International Inc.1$3,5002022
Merge Healthcare Incorporated60$3,1472022
KLS-Martin L.P.1$3,0002022
HEARTFLOW, INC.1$2,3502022
Genentech USA, Inc.1$1,2002022
Mallinckrodt Hospital Products Inc.1$8752022
Stryker Corporation1$4302022
Cochlear Americas1$1782022
Hikma Pharmaceuticals USA1$882022
Linvatec Corporation1$292022

By nature of payment

NatureRecordsAmount
Research payment254$1,133,626
Long term medical supply or device loan3$43,029
Debt forgiveness3$9,633
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$5,600
Space rental or facility fees (teaching hospital only)2$4,200
Education1$3,500
Food and Beverage61$3,236
Consulting Fee3$2,880

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Medtronic, Inc.$58,586Research paymentIn-kind items and servicesFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-12-31AngioDynamics, Inc.$30,000Long term medical supply or device loanIn-kind items and servicesAuryon Laser System 100-120 Vac Device, ET2022
2022-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2022
2022-12-31Stryker Corporation$430Debt forgivenessCash or cash equivalent2022
2022-12-31Linvatec Corporation$29Long term medical supply or device loanIn-kind items and servicesBEAMER ACCESSORIES Device, GENERAL SURGERY2022
2022-12-21Medtronic, Inc.$10,681Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-12-08Abbott Laboratories$500Research paymentCash or cash equivalentCONFIRM RX Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2022
2022-11-30Medtronic, Inc.$160Consulting FeeCash or cash equivalent2022
2022-11-28Travere Therapeutics, Inc.$300Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-11-22Merit Medical Systems Inc$9,025Debt forgivenessCash or cash equivalent2022
2022-11-22Regeneron Pharmaceuticals, Inc.$316Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-11-21Boston Scientific Corporation$2,620Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-11-21Boston Scientific Corporation$940Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-11-21Boston Scientific Corporation$940Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-11-17JAZZ PHARMACEUTICALS INC.$55,500Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-11-17Medtronic, Inc.$1,443Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-11-17Medtronic, Inc.$1,310Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-11-17Genentech USA, Inc.$1,200Space rental or facility fees (teaching hospital only)Cash or cash equivalentRituxan Biological, BioOncology/Immunology2022
2022-11-17Medtronic, Inc.$923Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-11-15Regeneron Pharmaceuticals, Inc.$633Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-11-09Abbott Laboratories$2,094Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-11-09Abbott Laboratories$524Research paymentCash or cash equivalentCONFIRM RX Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2022
2022-11-08Medtronic, Inc.$134Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-11-08Medtronic, Inc.$134Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-11-08Medtronic, Inc.$134Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-11-07Boston Scientific Corporation$9,448Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-11-07Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-11-07Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-11-02Regeneron Pharmaceuticals, Inc.$1,161Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-11-01Medtronic, Inc.$3,291Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-11-01Merge Healthcare Incorporated$87Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-10-27Medtronic, Inc.$1,443Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-10-26Regeneron Pharmaceuticals, Inc.$1,055Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-10-25UCB SA$22,750Research paymentCash or cash equivalentVimpat Drug, NeurologyA MULTICENTER, OPEN-LABEL, RANDOMIZED, ACTIVE COMPARATOR STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF2022
2022-10-19Boston Scientific Corporation$1,159Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-10-10Merge Healthcare Incorporated$19Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-10-09Merge Healthcare Incorporated$53Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-10-07Regeneron Pharmaceuticals, Inc.$633Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-10-03Boston Scientific Corporation$5,492Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-10-03Medtronic, Inc.$320Consulting FeeCash or cash equivalent2022
2022-09-29Abbott Laboratories$1,500Research paymentCash or cash equivalentSJM MASTERS SERIES Device, VascularA Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as2022
2022-09-29Medtronic, Inc.$1,443Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-09-29Medtronic, Inc.$948Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-09-29Abbott Laboratories$750Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$700Research paymentCash or cash equivalentSJM MASTERS SERIES Device, VascularA Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as2022
2022-09-29Abbott Laboratories$93Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$93Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$62Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$62Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$62Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$62Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-29Abbott Laboratories$31Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-09-28Regeneron Pharmaceuticals, Inc.$3,514Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-09-22Medtronic, Inc.$1,500Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-09-20Regeneron Pharmaceuticals, Inc.$4,793Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-09-20Boston Scientific Corporation$2,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-09-20Boston Scientific Corporation$1,807Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-09-20Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-09-20Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-09-20Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-09-20Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-09-15Travere Therapeutics, Inc.$3,810Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$3,352Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$3,242Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$3,179Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$3,007Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$3,007Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$2,759Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$2,732Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$2,692Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,317Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,317Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,317Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,317Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,251Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,250Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,224Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,168Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,141Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$1,141Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$300Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-15Travere Therapeutics, Inc.$279Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-09-13JAZZ PHARMACEUTICALS INC.$92,500Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-09-09Regeneron Pharmaceuticals, Inc.$5,079Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-09-09Terumo Medical Corporation$500Research paymentCash or cash equivalentPROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR2022
2022-09-08Medtronic, Inc.$1,738Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-09-08Abbott Laboratories$1,500Research paymentCash or cash equivalentTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart FailureSupporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)2022
2022-09-06Boston Scientific Corporation$8,442Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-09-06Medtronic, Inc.$922Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-09-01JAZZ PHARMACEUTICALS INC.$2,500Research paymentCash or cash equivalentRYLAZE Drug, HEMATOLOGY/ONCOLOGYAN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH2022
2022-09-01JAZZ PHARMACEUTICALS INC.$2,500Research paymentCash or cash equivalentRYLAZE Drug, HEMATOLOGY/ONCOLOGYAN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH2022
2022-09-01JAZZ PHARMACEUTICALS INC.$2,000Research paymentCash or cash equivalentRYLAZE Drug, HEMATOLOGY/ONCOLOGYAN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH2022
2022-08-24Abbott Laboratories$5,129Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-08-17Regeneron Pharmaceuticals, Inc.$800Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-08-16Boston Scientific Corporation$940Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-08-16Boston Scientific Corporation$179Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-08-16Merge Healthcare Incorporated$67Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Merge Healthcare Incorporated$67Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Merge Healthcare Incorporated$67Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Boston Scientific Corporation$51Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-08-16Merge Healthcare Incorporated$17Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Merge Healthcare Incorporated$17Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Merge Healthcare Incorporated$11Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Merge Healthcare Incorporated$11Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-16Merge Healthcare Incorporated$11Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-12Terumo Medical Corporation$1,920Research paymentCash or cash equivalentPROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR2022
2022-08-12Terumo Medical Corporation$1,076Research paymentCash or cash equivalentPROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR2022
2022-08-11Medtronic, Inc.$2,980Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-08-11Medtronic, Inc.$1,500Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-08-09Regeneron Pharmaceuticals, Inc.$211Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-08-04Medtronic, Inc.$922Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-08-03Medtronic, Inc.$4,230Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-08-03Abbott Laboratories$1,587Research paymentCash or cash equivalentCONFIRM RX Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2022
2022-08-02Esperion Therapeutics, Inc.$50Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-01Boston Scientific Corporation$814Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-07-27Medtronic, Inc.$1,500Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-07-27Medtronic, Inc.$240Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-07-22Terumo Medical Corporation$1,696Research paymentCash or cash equivalentPROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR2022
2022-07-21Regeneron Pharmaceuticals, Inc.$1,583Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-07-21Abbott Laboratories$1,250Research paymentCash or cash equivalentCARDIOMEMS Device, Heart FailureHemodynamic-GUIDEd Management of Heart Failure2022
2022-07-20Esperion Therapeutics, Inc.$1,352Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-18Boston Scientific Corporation$2,097Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-07-17Medtronic, Inc.$6,500Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-07-17Medtronic, Inc.$1,250Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-07-17Medtronic, Inc.$500Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-07-15Medtronic, Inc.$960Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-07-14Abbott Laboratories$500Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-07-13Abbott Laboratories$1,574Research paymentCash or cash equivalentCARDIOMEMS Device, Heart FailureHemodynamic-GUIDEd Management of Heart Failure2022
2022-07-08Medtronic, Inc.$2,980Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-07-08Regeneron Pharmaceuticals, Inc.$1,583Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-07-07Travere Therapeutics, Inc.$400Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2022
2022-07-05Boston Scientific Corporation$14,500Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-07-05Boston Scientific Corporation$4,098Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-07-05Veryan Medical Incorporated$1,428Research paymentCash or cash equivalentBioMimics 3D Vascular Stent System Device, Vascular StentA prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p2022
2022-07-05Veryan Medical Incorporated$1,200Research paymentCash or cash equivalentBioMimics 3D Vascular Stent System Device, Vascular StentA prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p2022
2022-07-01Esperion Therapeutics, Inc.$4Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-01Esperion Therapeutics, Inc.$1Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-30Regeneron Pharmaceuticals, Inc.$1,173Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-06-29Medtronic, Inc.$500Research paymentCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/GraftTLIF IDE Pivotal Study2022
2022-06-24Esperion Therapeutics, Inc.$1Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-23Regeneron Pharmaceuticals, Inc.$5,625Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-06-23Abbott Laboratories$63Research paymentCash or cash equivalentTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart FailureSupporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)2022
2022-06-22Medtronic, Inc.$2,049Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-06-22Merge Healthcare Incorporated$150Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-22Merge Healthcare Incorporated$150Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-22Merge Healthcare Incorporated$150Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-22Merge Healthcare Incorporated$23Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-22Merge Healthcare Incorporated$3Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-21Esperion Therapeutics, Inc.$1,352Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Esperion Therapeutics, Inc.$1,352Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Esperion Therapeutics, Inc.$1,352Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Esperion Therapeutics, Inc.$1,352Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Esperion Therapeutics, Inc.$1,352Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Boston Scientific Corporation$828Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-06-21Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Esperion Therapeutics, Inc.$32Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Esperion Therapeutics, Inc.$32Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-21Merge Healthcare Incorporated$16Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-16JAZZ PHARMACEUTICALS INC.$135,375Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-06-16Abbott Laboratories$124Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-06-08BTG International Inc.$3,500EducationCash or cash equivalentCYANOKIT Drug, treatment of acute cyanide intoxication2022
2022-06-07Boston Scientific Corporation$814Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-06-06Medtronic, Inc.$2,400Consulting FeeCash or cash equivalent2022
2022-06-02Hikma Pharmaceuticals USA$88Food and BeverageIn-kind items and services2022
2022-05-27Cochlear Americas$178Debt forgivenessCash or cash equivalentCochlear Device, Implantable hearing solution2022
2022-05-25Abbott Laboratories$4,450Research paymentCash or cash equivalentCONFIRM RX Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2022
2022-05-25Abbott Laboratories$1,471Research paymentCash or cash equivalentCARDIOMEMS Device, Heart FailureHemodynamic-GUIDEd Management of Heart Failure2022
2022-05-25Medtronic, Inc.$250Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-05-23Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-23Esperion Therapeutics, Inc.$32Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-05-20Merge Healthcare Incorporated$23Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-05-19Regeneron Pharmaceuticals, Inc.$527Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-05-12Medtronic, Inc.$1,443Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-05-12Medtronic, Inc.$1,443Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-05-12Regeneron Pharmaceuticals, Inc.$705Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2022
2022-05-12Medtronic, Inc.$601Research paymentCash or cash equivalentFLOWMET-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2022
2022-05-10Medtronic, Inc.$2,484Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2022
2022-05-04Abbott Laboratories$3,690Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2022
2022-05-04Abbott Laboratories$1,883Research paymentCash or cash equivalentSJM MASTERS SERIES Device, VascularA Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as2022
2022-05-02Medtronic, Inc.$3,680Research paymentCash or cash equivalentCARDIOBLATE Device, AblationTerminate AF2022
2022-05-02Boston Scientific Corporation$1,366Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTELEGANCE2022
2022-05-02Boston Scientific Corporation$565Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-28Merge Healthcare Incorporated$63Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022

The latest 200 records of 328.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Travis CountyAustin city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Austin, TX, county Travis County, TX, state Texas; placed by its city name.

MeasurePlace (city or town)
Austin, TX
County
Travis County, TX
State
Texas
Population B01003979,5391,330,01530,188,424
Population, 2020 census P1961,8551,290,18829,145,505
Median age B0100234.735.635.6
Under 18 B0100118.0%20.2%25.0%
65 and over B0100110.4%11.0%13.4%
Households B11001456,113583,74710,992,816
Foreign born B0500218.7%18.1%17.6%
Median household income B19013$93,658$99,611$78,476
Median family income B19113$128,808$131,256$94,599
Per capita income B19301$62,862$62,607$40,752
Poverty rate B1700112.0%10.9%13.8%
Unemployment rate B230254.7%4.6%5.3%
Civilian labor force B23025617,774799,52415,233,563
Mean commute (minutes) B0801323.725.226.7
Bachelor's degree or higher B1500359.6%56.6%33.8%
Housing units B25001483,071618,23612,128,515
Owner-occupied B2500343.4%52.1%62.6%
Renters B2500356.6%47.9%37.4%
Median home value B25077$555,300$523,000$283,800
Median gross rent B25064$1,729$1,744$1,403
White, not Hispanic B0300247.0%46.9%39.1%
Black B030027.3%7.8%11.9%
Hispanic or Latino B0300231.9%32.6%39.7%
Asian B030029.0%7.8%5.5%
American Indian and Alaska Native B030020.1%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Austin, TX.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.